arrow_back Back Filing freshness 10-Q Q1 FY2027 SEC EDGAR

Tilray Brands, Inc.

TLRY
$2.81 ▼ -0.16 (-5.22%) at close
Materials ·Medicinal Chemicals & Botanical Products ·USMedicinal Chemicals & Botanical Products
40 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
36
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

Tilray Brands, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $374.7M
Dividend Yield —
Revenue Growth 22.7% ↘
Op. Margin -9.4% ↘
ROIC -1.4% ↗
FCF / Share $-0.12
Trailing P/E —
Price / Book 0.3x
FCF Yield —
Debt / Equity 0.08
info Valuation on last close. End-of-day price, Nov 5, 2026.

40-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$257.15M
↑ +22.7% —
Net Income Profit after all expenses
$-43.14M
↓ -13297.8% —
Operating Margin Operating profit as % of sales
-9.4%
↓ -60.1% 14th
FCF / Share Free cash flow per share
$-0.12
↓ -9708.2% —
Long-Term Debt Long-term obligations
$118.05M
↓ -36.4% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
11
Returns ↑
32
Financial Health →
68
Cash Quality ↑
41

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 11 years · 40 quarters